(Q51363927)

English

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.

scientific article published on 17 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. (English)

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

0 references

Jens Juul Holst

5

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

7

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

1

object named as

Filip K Knop

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

author name string

K Aaboe

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

T Vilsbøll

3

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

A Vølund

4

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

T Krarup

6

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

publication date

17 January 2012

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

14

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

6

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

500-510

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

On the physiology of GIP and GLP-1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Validation of methods for measurement of insulin secretion in humans in vivo.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Beta cell function and its relation to insulin action in humans: a critical appraisal

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Evaluation of proposed oral disposition index measures in relation to the actual disposition index

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Accurate assessment of beta-cell function: the hyperbolic correction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

The hyperbolic equilibrium between insulin sensitivity and secretion

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Beta- and alpha-cell dysfunction in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Association of fasting glucagon and proinsulin concentrations with insulin resistance.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Use and abuse of HOMA modeling

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Reduced Incretin Effect in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Diminished Immunoreactive Gastric Inhibitory Polypeptide Response to a Meal in Newly Diagnosed Type I (Insulin-Dependent) Diabetics*

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01549.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01549.X

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/22171657

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51363927&oldid=1744743705"